CN112996528B - 肽及其医学用途 - Google Patents

肽及其医学用途 Download PDF

Info

Publication number
CN112996528B
CN112996528B CN201980074348.6A CN201980074348A CN112996528B CN 112996528 B CN112996528 B CN 112996528B CN 201980074348 A CN201980074348 A CN 201980074348A CN 112996528 B CN112996528 B CN 112996528B
Authority
CN
China
Prior art keywords
peptide
vegfr
ivr1
neovascularization
cys
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201980074348.6A
Other languages
English (en)
Chinese (zh)
Other versions
CN112996528A (zh
Inventor
梅诺蒂·鲁沃
达维德·罗谢洛
桑德罗·德法尔科
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Anbisheng Co ltd
Original Assignee
Anbisheng Co ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Anbisheng Co ltd filed Critical Anbisheng Co ltd
Publication of CN112996528A publication Critical patent/CN112996528A/zh
Application granted granted Critical
Publication of CN112996528B publication Critical patent/CN112996528B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/10—Peptides having 12 to 20 amino acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Diabetes (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Ophthalmology & Optometry (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Child & Adolescent Psychology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Dermatology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
CN201980074348.6A 2018-09-11 2019-09-11 肽及其医学用途 Active CN112996528B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
IT102018000008493 2018-09-11
IT201800008493 2018-09-11
PCT/IB2019/057636 WO2020053772A1 (en) 2018-09-11 2019-09-11 Peptides and medical uses thereof

Publications (2)

Publication Number Publication Date
CN112996528A CN112996528A (zh) 2021-06-18
CN112996528B true CN112996528B (zh) 2025-01-07

Family

ID=64607074

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201980074348.6A Active CN112996528B (zh) 2018-09-11 2019-09-11 肽及其医学用途

Country Status (8)

Country Link
US (1) US12441765B2 (enExample)
EP (1) EP3849582B1 (enExample)
JP (2) JP2022500465A (enExample)
KR (1) KR20210062649A (enExample)
CN (1) CN112996528B (enExample)
AU (1) AU2019337806B2 (enExample)
CA (1) CA3112169A1 (enExample)
WO (1) WO2020053772A1 (enExample)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2019340465B2 (en) * 2018-09-11 2025-08-14 Anbition S.R.L. Peptides and medical uses thereof

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH09510688A (ja) * 1993-12-15 1997-10-28 ボード・オヴ・リージェンツ，ザ・ユニヴァーシティ・オヴ・テキサス・システム Ｃｘｃインタークリン分子のペプチド阻害剤
EP0987274A1 (en) 1998-09-15 2000-03-22 Hoechst Marion Roussel Deutschland GmbH Factor VIIa Inhibitors
DE60118186T2 (de) 2000-05-12 2006-12-28 Vlaams Interuniversitair Instituut Voor Biotechnologie Vzw. Verwendung von inhibitoren des plazenta wachstumsfactors für die behandlung einer pathologischen angiogenese, pathologischen arteriogenese, entzündung, tumorbildung und/oder gefässdurchlässigkeit (ödem)
CA2695960A1 (en) * 2007-08-08 2009-03-12 The Board Of Regents Of The University Of Texas System Vegfr-1/nrp-1 targeting peptides
EP2723766A4 (en) * 2011-06-22 2015-05-20 Univ Indiana Res & Tech Corp COAGONISTS OF GLUCAGON / GLP-1 RECEPTOR
BR112017018665A2 (pt) * 2015-03-02 2018-04-24 The Board Of Trustees Of The University Of Illinois peptídeos para inibição de angiogênese
US10463710B2 (en) * 2015-04-27 2019-11-05 Mackay Memorial Hospital Short synthetic peptide for the treatment and/or prophylaxis of autoimmune and inflammatory disorders

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
Modulation of angiogenesis by a tetrameric tripeptide that antagonizes vascular endothelial growth factor receptor 1;Salvatore Ponticelli et al.;《J Biol Chem》;第283卷(第49期);摘要、第34252页右栏第3段-第34253页左栏第3段、第34257页右栏第4段、图1 *
Powerful anti-tumor and anti-angiogenic activity of a new anti-vascular endothelial growth factor receptor 1 peptide in colorectal cancer models;Valeria Cicatielloet et al.;《Oncotarget》;第6卷(第12期);摘要、第10564页右栏第5段-第10567页右栏第2段、图1 *

Also Published As

Publication number Publication date
EP3849582B1 (en) 2025-12-31
WO2020053772A1 (en) 2020-03-19
JP2024150757A (ja) 2024-10-23
AU2019337806B2 (en) 2025-08-14
CA3112169A1 (en) 2020-03-19
KR20210062649A (ko) 2021-05-31
US20220064216A1 (en) 2022-03-03
EP3849582A1 (en) 2021-07-21
US12441765B2 (en) 2025-10-14
JP2022500465A (ja) 2022-01-04
AU2019337806A1 (en) 2021-05-13
CN112996528A (zh) 2021-06-18

Similar Documents

Publication Publication Date Title
US20220313770A1 (en) Immunotherapy for angiogenic disease
US20170258868A1 (en) Peptides for Inhibiting Angiogenesis
JP2024150757A (ja) ペプチドおよびその医学的使用
CN113015539B (zh) 肽及其医学用途
US9249185B2 (en) Peptides for promoting angiogenesis and an use thereof
JP7112753B2 (ja) Ｄｓｇ２由来ペプチド
WO2022162030A1 (en) Peptides for inhibiting angiogenesis
HK1247573B (zh) 用於抑制血管生成的肽
HK1245149B (en) Wt1 immunotherapy for intraocular angiogenic disease

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant